Skip to main content

SCC Update: Defining and Managing High-Risk Cutaneous SCC

TO REGISTER: Scroll down and add to cart
ASDS Fellow Members and Residents: $49
Non-Members: $99

This activity reviews what constitutes high risk, including current staging and other considerations. The roles of Mohs/CCPDMA, nodal staging, adjuvant and neoadjuvant therapy including clinical trials, and anti PD1 systemic therapy for N2 and unresectable disease including success rates, major side-effects, and considerations in determining resectability versus appropriateness for systemic therapy are covered. CME: 1.00 AMA PRA Category 1 Credit™

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Apply current prognostic data to identify CSCC patients who are at risk for metastasis and death.
  • Determine ideal surgical approach or determine that patient is eligible for systemic therapy as an alternative to surgery.
  • Choose appropriate strategies for nodal staging, adjuvant therapy, and surveillance for recurrence.
Marc D. Brown, MD
Chrysalyne D. Schmults, MD

The American Society for Dermatologic Surgery (ASDS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASDS designates this avtivity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.